BEAM
Beam Therapeutics Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$27.23Close
$2.8BMarket cap
$20.60 – $37.9252-week range
Nov 3, 2026Next report
Highlights
Cautions
- Not in an uptrend 3 of 8 trend conditions
- Lagging the market RS 46 · weaker than 54% of stocks over 12 months
- Far from its high 28% below its 52-week high
- Results soon Nov 3, 2026, in 2 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
28%
1wk
up 13.2%
price change
1mo
up 11.4%
price change
12-month return
up 14%
market up 11% ·
its own down 1%
F-score
—
— Not assessed
Altman Z
5.48
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
2.2×
price / book
Earnings yield
down 15.5%
EBIT / enterprise value
Cheaper than
26%
of the market · expensive
Revenue growth
up 120%
year on year
EPS growth
—
latest quarter
Sales growth
down 94%
latest quarter · -419 pts
ROE
down 8%
return on equity
Free cash margin
down 258%
-$360.0M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
Repair signals
- Revenue reaccelerating (-83% then +120%)
Trade setup
ATR%
5.8%
$1.57 a day · 2×ATR $24.10
RS
46 / 99
vs the universe
Trend
3 / 8
trend template
Relative volume
0.8×
vs 50-day average
Up/down volume
0.89
50 sessions
Implied move
—
no option chain · report Nov 3, 2026
Trend template · 3 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: fails
- 50-day average above the 150 and 200-day: fails
- Price above the 50-day average: passes
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 21.7% over the year, from 84m to 102m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 4, 2026
Results reaction
Aug 4, 2026+3% vs market2 sessions after results
Financials
- Net -57%
- Free cash -258%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $24,000 | $51.8M | $60.9M | $377.7M | $63.5M | $139.7M |
| Operating income | -$132.8M | -$392.5M | -$338.5M | -$176.5M | -$415.6M | -$383.7M |
| Net income | -$194.6M | -$370.7M | -$289.1M | -$132.5M | -$376.7M | -$80.0M |
| Net margin | -810800% | -715% | -475% | -35% | -593% | -57% |
| Earnings per share | -$4.16 | -$5.77 | -$4.13 | -$1.72 | -$4.58 | -$0.81 |
| Free cash flow | -$112.1M | -$113.1M | -$26.4M | -$182.9M | -$356.2M | -$360.0M |
| Free cash margin | -467075% | -218% | -43% | -48% | -561% | -258% |
| Cash | $162.2M | $560.0M | $232.8M | $435.9M | $282.0M | $294.9M |
| Shareholders' equity | $245.6M | $826.7M | $733.5M | $981.3M | $733.5M | $1.2B |
| Shares outstanding | 57.25m | 68.39m | 71.28m | 81.63m | 83.63m | 101.75m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 4, 2026 | Quarterly ↗ | Jun 30, 2026 | 35d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Feb 24, 2026 | Annual ↗ | Dec 31, 2025 | 55d |
| Nov 4, 2025 | Quarterly ↗ | Sep 30, 2025 | 35d |
| Aug 5, 2025 | Quarterly ↗ | Jun 30, 2025 | 36d |
| May 6, 2025 | Quarterly ↗ | Mar 31, 2025 | 36d |
| Feb 25, 2025 | Annual ↗ | Dec 31, 2024 | 56d |
| Nov 5, 2024 | Quarterly ↗ | Sep 30, 2024 | 36d |
| Aug 6, 2024 | Quarterly ↗ | Jun 30, 2024 | 37d |
| May 7, 2024 | Quarterly ↗ | Mar 31, 2024 | 37d |
| Feb 27, 2024 | Annual ↗ | Dec 31, 2023 | 58d |
| Nov 8, 2023 | Quarterly ↗ | Sep 30, 2023 | 39d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 4, 2026 | Results ↗ |
| Jun 8, 2026 | Shareholder vote ↗ |
| May 7, 2026 | Results ↗ |
| Mar 5, 2026 | Agreement ended ↗ |
| Feb 24, 2026 | Material agreement · Results · New obligation ↗ |
| Feb 12, 2026 | Material agreement ↗ |
| Feb 5, 2026 | Director or officer change ↗ |
| Jan 12, 2026 | Results · Regulation FD ↗ |
| Dec 11, 2025 | Acquisition or disposal ↗ |
| Nov 4, 2025 | Results ↗ |
| Aug 5, 2025 | Results ↗ |
| Jul 3, 2025 | Unregistered share sale ↗ |